AberrantepithelialmorphologyandpersistentepidermalgrowthfactorreceptorsignalinginamousemodelofrenalcarcinomaZacharyS.MorrisandAndreaI.McClatchey1MassachusettsGeneralHospitalCenterforCancerResearchandDepartmentofPathology,HarvardMedicalSchool,Charlestown,MA02129EditedbyRobertA.Weinberg,WhiteheadInstituteforBiomedicalResearch,Cambridge,MA,andapprovedApril24,2009(receivedforreviewFebruary24,2009)Theepidermalgrowthfactorreceptor(EGFR)hasfrequentlybeenimplicatedinhyperproliferativediseasesofrenaltubuleepithelia.WehaveshownthattheNF2tumorsuppressorMerlininhibitsEGFRinternalizationandsignalinginacellcontact–dependentmanner.Interestingly,despitethepaucityofrecurringmutationsinhumanrenalcellcarcinoma(RCC),homozygousmutationoftheNF2geneisfoundin⬇2%ofRCCpatientsamplesintheSangerCOSMICdata-base.ToexaminetherolesofMerlinandEGFRinkidneytumorigen-esis,wegeneratedmicewithatargeteddeletionofNf2intheproximalconvolutedepitheliumusingaVillin-Cretransgene.Allofthesemicedevelopedintratubularneoplasiaby3months,whichprogressedtoinvasivecarcinomaby6–10months.Kidneysfromthesemicedemonstratedmarkedhyperproliferationandaconcom-itantincreaseinlabel-retainingputativeprogenitorcells.Earlylumen-ﬁllinglesionsinthismodelexhibitedhyperactivationofEGFRsignal-ing,alteredsolubilityofadherensjunctionscomponents,andlossofepithelialpolarity.RenalcorticalepithelialcellsderivedfromeitherearlyorlatelesionsweredependentonEGFforinvitroproliferationandwerearrestedbypharmacologicinhibitionofEGFRorre-expres-sionofNf2.Thesecellsformedmalignanttumorsupons.c.injectionintoimmunocompromisedmicebeforeinvitropassage.TreatmentofVil-Cre;Nf2lox/loxmicewiththeEGFRinhibitorerlotinibhaltedtheproliferationoftumorcells.ThesestudiesgiveaddedcredencetotheroleofEGFRsignalingandperhapsNf2deﬁciencyinRCCanddescribearareandvaluablemousemodelforexploringthemolecularbasisofthisdisease.EGFR兩kidney兩Merlin兩Nf2兩renalcellcarcinomaRenalcellcarcinomas(RCC)arisefromrenaltubuleepithelialcellsandaccountfor85%ofkidneytumors(1).MostcasesofRCCaresporadic(⬎97%),yethereditarysyndromes,suchasVonHippel-Lindau,hereditarypapillaryrenalcarcinoma,Birt-Hogg-Dube´,hereditaryleiomyomatosisandrenalcellcancer,andtuber-oussclerosiscomplex,contributetodiseaseincidence(2).Somaticmutationsinthegenesassociatedwiththesesyndromes—VHL,c-Met,BHD,FH,TSC-1,andTSC-2,respectively—havebeenidentifiedinsporadicRCC(3,4).Studiesofthecellularconse-quencesofspecificgeneticmutationsassociatedwithhereditaryRCCshavespawnedmuchofourcurrentunderstandingoftumor-igenesisfromrenaltubuleepithelia.Yetthesewell-studiedgeneticeventsdonotaccountforthetotalityofsporadictumorigenesisinRCC,suggestingthatadditionalcausativemutationsremainun-identified(5).StudiesofRCCpathogenesishavebeenlimitedbythepaucityofgeneticallydefinedanimalmodels.Surprisingly,micewithgeneticdisruptionsofVHL,c-Met,orFHdonotdevelopkidneytumors(6–8).Todate,onlymutationofBHD,TSC-1,TSC-2,ortheAPCtumorsuppressoryieldstumorsreminiscentofRCCingeneticallyengineeredanimals(9–14).YetmutationofthesegenesisrareinsporadicRCC,andtheseanimalmodelsprovideanincompletepictureofthediversemolecularmechanismsimplicatedinthisdisease.Moreover,noneofthesemodelsisidealforstudyingrenaltumorigenesis,owingtohighneonatalmortality(BHD,APC),longlatencyoftumordevelopment(TSC-1),orlackoftissue-specifictargeting(TSC-1,TSC-2)(9–14).AdditionalandimprovedanimalmodelsofRCCareneededtoadvancebasicandpreclinicalstudiesofrenalepithelialneoplasia.ThepaucityofrecurrentgeneticalterationsthathavebeenidentifiedinRCCisstriking.AccordingtotheSangerCatalogofSomaticMutationsinCancer(COSMIC)database(15),only3genesaremutatedatafrequencygreaterthan4%inRCCpatientsamples(VHL,42%;CDKN2A,12%;andKIT,8%).Thefactthathomozygousmutationoftheneurofibromatosistype2(NF2)tumorsuppressorgenewasidentifiedin⬇2%(2of126)oftheRCCsamplesinthisdatabaseisthereforepotentiallysignificant,espe-ciallyinlightoftheassociationsbetweenaberrantepidermalgrowthfactorreceptor(EGFR)signalingandbothRCCandNf2(16–20).WerecentlydemonstratedthattheNf2tumorsuppressorMerlinisacriticalregulatorofEGFR(17,21).InavarietyofcellularcontextsMerlincoordinatestheinhibitionofEGFRsig-nalingwiththeestablishmentofstableadherensjunctions(AJs)(22),therebymediatingcontact-dependentinhibitionofprolifera-tion.ItiswelldocumentedthatEGFRanditsligands,EGFandTGF-␣,arefrequentlyoverexpressedinmanyformsofRCC(16,18,19,23,24),andactivationofEGFRhasbeenimplicatedinVHL-associatedRCC(20,25,26).EGFligandsareessentialfortheproliferationofmanyhumanRCCcelllines,andinhibitorsofEGFRantagonizeRCCcelldivisioninvitroandinvivo(18,27–29).ClinicaltrialshavedemonstratedsomeefficacyoftheEGFR/ErbB2dualkinaseinhibitorlapatinibforadvanced-stageRCC(30).However,atpresentthereisnoanimalmodelofEGFR-drivenRCC;suchamodelwouldbevaluableforidentifyingpredictorsand/ormodifiersofclinicalresponsetoEGFR-targetedtherapies.InlightofthecontributionofEGFRtokidneytumorigenesis,thedemonstratedroleforMerlin/Nf2inregulatingEGFR,andpre-liminaryevidenceimplicatingmutationofNf2insomeRCCpatientsamples,wehypothesizedthatNf2mutationwouldcontributetotumorigenesisfromrenaltubuleepithelialcellsinamousemodel.WefoundthattargetedinactivationofNf2inmouseproximalconvolutedtubules(PCT),thesiteoforiginformosthumanRCC,ledtomultifocaltumordevelopmentfeaturinglumen-fillingneo-plasiathatprogressedtoinvasivecarcinoma.Thesetumorsex-pressedmarkerscharacteristicofhumanRCCanddisplayedab-errantEGFRsignalingandproliferation.Infact,pharmacologicinhibitionofEGFRcompletelyhaltedtheproliferationofNf2-deficientrenaltumorcellsinvivo.Authorcontributions:Z.S.M.andA.I.M.designedresearch;Z.S.M.performedresearch;Z.S.M.andA.I.M.contributednewreagents/analytictools;Z.S.M.andA.I.M.analyzeddata;andZ.S.M.andA.I.M.wrotethepaper.Theauthorsdeclarenoconﬂictofinterest.ThisarticleisaPNASDirectSubmission.1Towhomcorrespondenceshouldbeaddressed.E-mail:mcclatch@helix.mgh.harvard.edu.Thisarticlecontainssupportinginformationonlineatwww.pnas.org/cgi/content/full/0902031106/DCSupplemental.www.pnas.org兾cgi兾doi兾10.1073兾pnas.0902031106PNAS兩June16,2009兩vol.106兩no.24兩9767–9772GENETICSResultsTodeterminewhetherthelossofNf2cancontributetotumorigenesisinthekidney,wecrossedNf2lox/loxmicewithVillin(Vil)-Cremice.OnthebasisofthereportedexpressionofVil-Cre,weexpectedthatthesemicewouldexhibitconstitutivelossofNf2intherenaltubuleepitheliaofthePCT(31).WeconfirmedthisbycrossingVil-Cre;Nf2lox/loxmicewithmicecarryingaGtRosa26lox/stop/lox␤-galactosidasereportertrans-gene(R26LSL-LacZ).Bothchemicaldetectionof␤-galactosidaseactivityinwhole-mountandparaffinsectionaswellasimmunohistochemicallabelingusinga␤-galactosidase–specificantibodyrevealedCreactivityinthecorticalrenaltubuleepitheliaofVil-Cre;Nf2lox/loxmicebutnotinNf2lox/loxcontrols[supportinginformation(SI)Fig.S1AandB].CostainingwiththePCT-specificLotustetragonolobusagglutinin(32)confirmedexclusivetargetingofthePCTepithelia(Fig.S1B).Immu-noblottingofdissectedrenalcortexlysatesrevealedamarkedreductioninMerlinlevels,confirmingthatwehadachievedtargetedinactivationofNf2(Fig.S1C).AllVil-Cre;Nf2lox/loxmicewereruntedfrombirthandoccasionallydiedintheperinatalperiodbetweenembryonicday17andpostnatalday3.Vil-Cre;Nf2lox/loxmicethatsurviveduntilweaning(⬇10%ofallpups)livedto⬇10monthsofage.Allofthesemicedevelopedlumen-fillingintratubularneoplasiaby3months(Fig.1A).Lesionswereapparentasearlyas15daysofageandmostcommonlyinitiatedinthecorticomedullaryjunctionasprojectionsofatypicalepithelialcellsintothePCTlumen(Fig.1A).By6monthsthesizeandnumberoftumorswasgreatlyincreased,displacinglargeareasofnormalrenaltissueandpenetratingtubulebasementmembraneasinvasivecarcinomas.HeterozygousVil-Cre;Nf2lox/⫹mice,ontheotherhand,wereindistinguishablefromNf2lox/loxcontrols(notshown).RenaltumorsinVil-Cre;Nf2lox/loxmicestainedpositiveforvimentin(Fig.1B).Immunoblottingofkidneycortexlysateindicatedthattheselesionswerealsogalectin-3positive(Fig.1C).Vimentinandgalectin-3areestablishedmarkersofclearcellRCCinhumans(33).ToascertainwhetherrenaltubuletumorsthatdevelopinVil-Cre;Nf2lox/loxmicederivefromadevelopmentallyand/orregionallyspecificcellpopulation,wedeletedNf2intheadultkidneyusingtheIFN-␣–inducibleMx1-Cretransgene.TheMx1promoterdrivesCre-recombinaseactivityinepithelialcellsofthecollectingductandthethickascendingloopofHenleinthenephronbutnotinthePCT(34).Mx1-Cre;Nf2lox/loxmicealsodevelopedlumen-fillingrenaltubuleneoplasiawithin6monthsofMx1-Creinduction(Fig.1A).Consistentwiththedistallocationoftheselesionsinthenephron,kidneysofMx1-Cre;Nf2lox/loxmicedisplayeddilationofupstreamtubulesupontumordevelopment,likelyduetoblockedurinaryflow.ThiswasunderstandablynotprominentinVil-Cre;Nf2lox/loxmice,whichdevelopedmoreproximaltumorsinthePCT.Never-theless,thedevelopmentofmorphologicallysimilarlesionsinVil-Cre;Nf2lox/loxandMx1-Cre;Nf2lox/loxmicesuggeststhatMerlinisanessentialregulatorofproliferationacrosstherenaltubuleepitheliumandfurthersupportsthenotionthatsomaticlossofNf2maycontributetosporadicrenaltumorigenesisinhumans.Veryfewcellsareproliferatinginthenormaladultmousekidney.Incontrast,renaltubulecarcinomasinVil-Cre;Nf2lox/loxmicewerehyperproliferative,displayingagreaterthan7-foldincreaseinKi67-andphosphorylatedhistone3(PH3)-positivenucleiandinthenumberofnucleilabeledbyBrdUduringashort3-hpremortemlabeling(Fig.2AandB;datanotshown).Inaddition,Vil-Cre;Nf2lox/loxkidneysexhibitedamarkedin-creaseinthenumberofBrdUlabel-retainingputativepro-genitorcells(35–37)duringa1-weekpulse/2-weekchaseexperiment(Fig.2CandD).Notably,thisincreaseinprolif-erationwasaccompaniedbyadramaticincreaseinphospho-tyrosinelevelswithinbothearlyandlatelesions(Fig.3A).Immunoblottingdemonstratedstrongandprogressiveactiva-tionofEGFR,itsprincipledimerizationpartnerErbB2,anditsdownstreamtargetsAkt,MAPK,andSTAT-3(Fig.3B).ImmunohistochemistryconfirmedthattheactivationofthesetargetswasrestrictedtoNf2-deficienttumors(Fig.3C).Im-portantly,wedidnotdetectsignificantdifferencesintheexpressionofEGFligandsinNf2lox/loxandVil-Cre;Nf2lox/loxkidneys(Fig.S2A).WepreviouslyfoundthatMerliniscriticalfortheestablishmentofstableAJsinseveraltypesofculturedcells(22).Intriguingly,althoughequivalentlevelsofcoreAJcomponentswerepresentinrenalcorticallysatesderivedfromNf2lox/loxandVil-Cre;Nf2lox/loxkidneys,wenotedastrikingdifferenceintheirdetergentsolubilityintheabsenceofMerlin(Fig.4A).Bothp120-and␤-cateninexhibitedgreatlyenhanceddetergentsolubilityinVil-Cre;Nf2lox/loxkidneys.ThiscouldbeconsistentwithafailuretostabilizetheseABCFig.1.TargetedlossofNf2inrenaltubuleepitheliagivesrisetovimentin-andgalectin-3–positivetumorsthatprogresstoinvasivecarcinoma.(A)AllVil-Cre;Nf2lox/loxmicedevelopedsmallintratubularneo-plasticgrowthsofatypicalepithelialcellsby30daysofage.Thesegrewtolargetumorswithin3monthsandprogressedtoinvasivecarcinomasby6months.Renaltumorsinthesemiceconsistentlygrewintothetubulelumen,ofteninitiatingwithapolypoidmorphology(LowerLeft).TheVil-Cre;Nf2lox/loxkidneyphenotypeisrecapitulatedininducibleMx1-Cre;Nf2lox/loxmice,whichtargetCre-recombinaseexpressiontothecol-lectingduct(Right).(B)TumorsinVil-Cre;Nf2lox/loxkid-neysstainpositivebyimmunohistochemistryforvi-mentin.InNf2lox/loxcontrolkidneysvimentinisseenonlyinglomeruli,arterioles,andinterstitialﬁbro-blasts.(C)RenalcortexlysatesfromVil-Cre;Nf2lox/loxmicedisplayincreasedexpressionofgalectin-3byim-munoblot.Together,vimentinandgalectin-3arehis-tologicmarkersforclearcellRCCinhumans(33).ForAandB,thesectionsshownarerepresentativeof3mice⫻2slidespermouse⫻3sectionsperslide⫻2kidneyspersection⫻⬇10lesionsperkidney⫽⬇360lesionsexamined.N⫽normaltubules,G⫽glomeruli.*Lesion/tumor.9768兩www.pnas.org兾cgi兾doi兾10.1073兾pnas.0902031106MorrisandMcClatcheyproteinsattheinsoluble,cytoskeleton-associatedAJcomplexintheabsenceofMerlin.Indeed,immunohistochemicalstainingdemon-stratedthat␤-cateninwasnotstronglylocalizedtocell–cellcontactsinNf2-deficientlesions(Fig.4B).Interestingly,giventhepurportednecessityofAJsinestablishingapico-basolateralpolarity(38–40),wealsofoundthatcellswithinVil-Cre;Nf2lox/loxneoplastictissuesfailedtoproperlylocalizetheapicalmarkersezrinandNa/Hexchangerregulatoryfactor(NHERF)-1andtheapicaltightjunc-tionmarkerZO-1(Fig.4C,Fig.S2B).Notably,increasedEGFRsignalingwasnotseparatedtemporallyfromalteredlocalizationofjunctionalproteinsandpolaritymarkers,andtheseeffectsofNf2deficiencywereapparentintheearliestdetectablelesionsin2-week-oldVil-Cre;Nf2lox/loxmice(notshown).TofurtherinvestigatethecellularandmoleculareffectsofNf2deficiencyinrenaltubuleepithelialcells,wederivedprimaryepithelialcellculturesfromtherenalcortexofNf2lox/lox,Vil-Cre;Nf2lox/lox,andIFN-inducedMx1-Cre;Nf2lox/loxmice.OnlycellsfromVil-Cre;Nf2lox/loxandMx1-Cre;Nf2lox/loxcortexgrewtoconflu-enceandsurvivedpassaging(Fig.S3A).LikeotherNf2-/-cells,Nf2-deficientkidneyepithelialcellsfailedtoundergocontact-dependentinhibitionofproliferation,aphenotypethatwasre-versedbyviralre-expressionofNf2(Fig.S3B–D).Notably,wealsofoundthatNf2-deficientrenalepithelialcellsrequiredEGFforgrowthincultureandwerestronglyandreversiblygrowthsup-pressedbytreatmentwiththeEGFRtyrosinekinaseinhibitorerlotinib(Fig.S3CandD).Remarkably,Nf2-deficientrenalABDCFig.2.Vil-Cre;Nf2lox/loxkidneysdisplayheightenedepithelialcellproliferationandanincreasednumberoflabel-retainingputativeprogenitorcells.(A)Three-month-oldVil-Cre;Nf2lox/loxkidneysdisplayedin-creasedproliferationofcellsmostlylocalizedtolu-men-ﬁllingneoplasticgrowths,asmeasuredbynuclearstainingofKi67(immunohistochemistry)andPH3(green,immunoﬂuorescence).Renalepithelialcellsaredisplayedinredonimmunoﬂuorescenceim-ages.(B)Quantiﬁcationper100cellsrevealeda⬇7-foldincreaseinKi67-positivenucleiintheVil-Cre;Nf2lox/loxrenalcortexrelativetocontrols.(CandD)BrdUpulse–chaseexperiments(1-weekpulse,2-weekchase),previouslyreportedtoidentifyputativeprogen-itorcells(57),demonstrateda⬇5-foldincreaseinthenumberoflabel-retainingcellsintheVil-Cre;Nf2lox/loxrenalcortexrelativetocontrols.Thesectionsshownarerepresentativeofmultiplemice,sections,andlesionsasdeﬁnedinthelegendtoFig.1.ABCFig.3.TumorsinVil-Cre;Nf2lox/loxkidneysarefociofactivatedEGFRsignaling.(A)Immunoﬂuorescentde-tectionusingthepY100antibody(green)revealedamarkedincreaseinphosphotyrosinesignalinginearly(Right)andlate(Middle)lesionsinVil-Cre;Nf2lox/loxkidneys.Renalepithelialcellsaredisplayedinred.(B)ImmunoblotdemonstratedactivationofEGFR,itspre-ferreddimerizationpartnerErbB2,anditsdown-streameffectorsinrenalcortexlysatesfrom3-and6-month-oldVil-Cre;Nf2lox/loxmice.(C)Immunohisto-chemicaldetectionofphosphorylatedAkt,MAPK,andSTAT-3inparafﬁnsectionsof3-month-oldkidneysdemonstratedthathyperactivationoftheseEGFRef-fectorswasconﬁnedtoneoplasticlesionsinVil-Cre;Nf2lox/loxmice.Thesectionsshownarerepresenta-tiveofmultiplemice,sectionsandlesionsasdeﬁnedinthelegendtoFig.1.MorrisandMcClatcheyPNAS兩June16,2009兩vol.106兩no.24兩9769GENETICSepithelialcellswerecapableofformingmalignants.c.tumorsinnudemicewithoutinvitropassage(Fig.S3EandF).Thesetumorsdisplayedanintriguingmixedhistology,withsomeareasseemingtoregenerateatubulararchitecturethatwascompromisedbylumenfilling.Collectively,thesedatasuggestedthataberrantEGFRsignalingmayunderliethetumorigenicconsequencesofNf2deficiencyinthekidneyepitheliuminvivo.Totestthishypothesis,wetreated12–16-weekoldVil-Cre;Nf2lox/loxmicewitherlotinibbyi.p.injection,twicedailyfor10days.Erlotinibtreatmentcompletelyhaltedtheover-proliferationofrenaltumorcellswithinthesemice,restoringwild-typelevelsofKi67-andPH3-positivenuclei(Fig.5A).Thiswasassociatedwithdecreasedactivationofclassicdownstreamsignal-ingeffectors,suchasAkt,MAPK,andSTAT-3;notably,erlotinibalsoreducedtheactivationofnonclassicEGFReffectors,suchascaveolin-1(Fig.5BandC).Consistentwiththecytostaticeffectsobservedinvitro(Fig.S3CandD),erlotinibtreatmentdidnotinduceapoptosisornecrosisinrenaltumorsfromVil-Cre;Nf2lox/loxmice(notshown).DiscussionInthisworkwepresentageneticallyengineeredmousemodelofrenalepithelialcelltumorigenesis.TheVil-Cre;Nf2lox/loxmousejoinsashortlistofgeneticallydefinedmodelsofRCCandisthefirsttorecapitulatetheactivationofEGFRsignalingthatisoftenreportedinhumanRCC.TargetedlossoftheNf2tumorsuppressorinrenaltubuleepithelialcellsgivesrisetotumordevelopmentwith100%penetrance.LesionswithintheNf2-deficientrenaltubuleepitheliadevelopviaareproducibleprogressionfromlumen-fillingintratubularneoplasiathatdevelopsoverthecourseof3to4monthstoinvasivecarcinomaby6–10months.ThesetumorsdisplayhistologicfeaturesandexpressmarkersthatarediagnosticofhumanclearcellRCC.TreatmentofthesemicewiththeEGFRtyrosinekinaseinhibitorerlotinibdemonstratedthatEGFRsig-nalingwasnecessaryfortheover-proliferationobservedinthesetumors.Nf2-deficientepithelialcellsderivedfromearlyorlatelesionsinthesekidneysdonotundergocontact-dependentinhibi-tionofproliferationbutareantagonizedbypharmacologicinhibi-tionofEGFRsignaling.Thesecellscanbepassagedrepeatedlyinculturebut,remarkably,arecapableofgeneratingmalignanttu-morsupons.c.injectionintoimmunocompromisedmicebeforeinvitropassage.Thismousemodelandcellsderivedfromitmaythereforeproveusefulforexamininginvivomechanismsofresis-tanceorsensitivitytoEGFR-targetedtherapeuticsinthekidney.TherobustactivationofdownstreamEGFRsignalingpathwaysinABCFig.4.TumorcellsinVil-Cre;Nf2lox/loxkidneysexhibitincreasedsolubilityofAJcomponentsandalossofpolarity.(A)Rigorous1%SDSsolubilizationdemon-stratedequivalentexpressionofAJcomponents.Agentler0.1%SDSsolubilizationrevealedstarkdiffer-encesinthesolubilityoftheAJcomponents,p120-and␤-catenin,betweenVil-Cre;Nf2lox/loxandNf2lox/loxkid-neylysates.(B)Immunohistochemicalstainingdemon-stratedthatthischangeinsolubilitycorrelatedwithalossof␤-cateninlocalizationtocell–cellcontactsinneoplasticcellsof3-month-oldVil-Cre;Nf2lox/loxmice.(C)HistologicexaminationoftheapicalmarkersNHERF-1(green,immunoﬂuorescence)andezrin(im-munohistochemistry)showedalossofcellpolarityinearlyintratubulegrowthsarisinginVil-Cre;Nf2lox/loxkidneys.Renalepithelialcellsaredisplayedinredonimmunoﬂuorescenceimages.Thesectionsshownarerepresentativeofmultiplemice,sections,andlesionsasdeﬁnedinthelegendtoFig.1.BDCAFig.5.ErlotinibtreatmentofVil-Cre;Nf2lox/loxmicerestoreswild-typelevelsofproliferationtoNf2-deﬁcientrenaltubuleepithelia.(AandB)Twelve-to16-week-oldVil-Cre;Nf2lox/loxmiceweretreatedbyi.p.injectionof100mg/kgerlotinibtwicedailyfor10days.Erlotinibtreatmentrestoredwild-typelevelsofprolif-erationinVil-Cre;Nf2lox/loxmice,asassayedbyquanti-ﬁcationofKi67(immunohistochemistry)andPH3(green,immunoﬂuorescence)positivenucleiper100cells.Statisticalsigniﬁcancewasdeterminedbyone-tailed,independentsamples,parametricttest,P⫽0.00085.(C)Renaltumorsinerlotinib-treatedmiceexhibiteddecreasedactivationofEGFRsignalingef-fectorsbyimmunohistochemistry.Thesectionsshownarerepresentativeofmultiplemice,sections,andle-sionsasdeﬁnedinthelegendtoFig.2.(D)Immunoblotof0.1%SDSrenalcortexlysatesconﬁrmeddecreasedactivationofEGFR,itsdimerizationpartnerErbB2,anditsdownstreameffectorsinerlotinibtreatedVil-Cre;Nf2lox/loxmiceascomparedwithuntreatedcon-trols.Interestingly,targetingEGFRsignalingalsoseemedtonormalizethesolubilityof␤-catenin.9770兩www.pnas.org兾cgi兾doi兾10.1073兾pnas.0902031106MorrisandMcClatcheythismodelwillprovideanexcellentmetricforexploringandquantifyingthemoleculareffectsofsuchinterventions.TheVil-Cre;Nf2lox/loxmousegivesaddedcredencetotheroleoftheEGFRpathwayinRCCandprovidesanexcellenttoolforinvestigatingthemolecularmechanismsthatcontributetoEGFR-dependenttumorigenesisinthekidney.WepreviouslyreportedthatpersistentEGFRsignalingdrivesthelossofcontact-dependentinhibitionofproliferationexhibitedbyprimaryculturedNf2-deficientcellsofseveraldifferenttypes(17,21).Herewedemon-strateacausalroleforaberrantEGFRsignalinginNf2-associatedtumorigenesisinvivo.Inculturedcells,MerlinantagonizesEGFRsignalinginacontact-dependentmannerbycoordinatingtheestablishmentofstableAJswithinhibitionofEGFRinternaliza-tion,therebylimitingaccessofEGFRtoitsdownstreameffectors(17,22).InadditiontothecanonicalEGFReffectors,wefoundthatNf2-deficientkidneylysatesexhibitmarkedlyelevatedlevelsofphosphorylatedcaveolin-1(Fig.5C),whichisdownstreamofEGFRactivationandpermissivetocaveolae-mediatedendocytosis,1of2majorroutesofEGFRinternalization(41–43).ThissupportsthenotionthatMerlincanalsoregulateEGFRendocytosisinvivo.HerewealsopresentevidencethatMerlinstabilizesAJsinvivoasitdoesincellculture(22).Thus,incontrasttomembrane-boundE-cadherin,bothp120-and␤-cateninfailtolocalizetoabiochem-icallyinsolublesubcellularcompartmentintheabsenceofMerlin(Fig.4A).ThiscouldreflectafailuretolinkE-cadherintetramerstotheinsolublecytoskeletonandtherebyformmatureAJs.AlthoughclinicaltrialsthatexaminedtheefficacyofEGFRinhibitorsinRCCwerelargelydisappointing,thedualEGFR/ErbB2kinaseinhibitorlapatinibhasshownefficacyagainstthera-py-resistantRCCtumorsthatover-expressEGFR(30).Notably,EGFRiscapableofsignalingfromheterodimericEGFR–ErbB2complexesintherenalepitheliumand,althoughrare,co-overexpressionofthese2proteinsisassociatedwithpooroutcomeinRCC(44,45).WefoundmarkedlyincreasedphosphorylationofbothEGFRandErbB2intheVil-Cre;Nf2lox/loxrenalcortex,sug-gestingthatMerlinantagonizesactivationofErbB2,perhapsviaregulationofEGFR–ErbB2heterodimers.PerhapsretrospectiveanalyseswillrevealNF2deficiencyorderegulationasapredictorofpatientresponsetolapatinibinRCC.Interestingly,in3-dimen-sionalmammaryepithelialcultures,aberrantErbB2activitydriveslossofpolarityandlumenfilling(46),bothofwhichareprominentfeaturesoftheearlylesionsthatdevelopintheNf2-deficientkidney.TogetherwiththeknownroleofAJsintheestablishmentofapico-basolateralcellpolarity(38,39),theseobservationsmaysuggestabroaderroleforMerlinincoordinatingErbBsignalingwiththeestablishmentofcellpolarityinvivo.Notably,wealsoobserveEGFR-dependenthyperactivationofAktintherenalcortexofVil-Cre;Nf2lox/loxmice.AktsignalingcanbeproximallyregulatedbyPI3-kinase,mammaliantargetofrapamycin,andphosphataseandtensinhomolog(PTEN)—eachofwhichcontrib-utestoRCCwhendisrupted(47–50).ThismousemodelmayfurthersupporttheimportanceofAktsignalinginRCCandbeusefulinstudyingthetumorigeniceffectsofthispathway.PreliminarydatafrompatientsamplesintheSangerCOSMICdatabasesuggestthatNF2maybedisruptedinsomecasesofsporadicRCC(15).Ourfindingswarrantamorerigorousinvesti-gationofthispossibilityacrossalargesetofsporadicRCCtumors.TheabsenceofaclearincreaseinkidneytumorsusceptibilityinNF2patientscouldreflectthefactthatNF2israreandcompro-miseslifeexpectancyinmostpatientsbeforetheaverageageofonsetofRCC.Alternatively,additionalcooperatingmutationsmaybenecessaryforNF2-drivenRCCinhumans,wheresomaticinactivationofNF2likelyoccursinindividualcellsinanotherwisewild-typeorheterozygous-mutantepithelium.Infact,thismodelmaybevaluableinidentifyingsuchcooperatingmutations.AlthoughwetargetedlossofNf2inrenalepitheliathroughoutentireregionsofthenephron,wecommonlyobservedpolypoidtumorformation,ofteninitiallysurroundedbynormal-lookingepithelialcells(Fig.1).ThepervasiveexpressionandactivityofaRosa26-driven␤-galactosidasereporteracrosstheepitheliumtar-getedbybothVillin-andMx1-CretransgenesarguesagainstthepossibilitythatthisreflectsselectiveexcisionofNf2inafewcellsoftherenalepithelialmonolayer.Similarly,therapidonsetandmultiplicityofearlylesionssuggeststhatcooperatingeventsarenotrequiredfortheinitiationoftumorigenesisinthismodel.Alterna-tively,theobservationofpolypoidtumorssurroundedbyapparentlynormalNf2-deficientepithelialcellsmaysuggestthataspecificcelloforiginispreferentiallyaffectedbylossofNf2.MountingevidencefromtargetedinactivationofNf2inothertissuessuggeststhattissueprogenitorcellsareparticularlysensitivetolossofMerlin(M.Curto,S.Benhamouche,A.Gladden,andA.I.M.,unpublisheddata).Infact,Nf2deficiencyresultsinadramaticincreaseinthenumberoflabel-retainingputativeprogenitorcellsinthekidney,andpolypoidtumorsintheNf2-deficientrenalepitheliuminitiateatthecorticomedullaryjunction,aregionthoughttoharbortheprogenitorcellnicheintheadultkidney(35–37).ItistemptingtospeculatethatakidneyprogenitorcellisparticularlysensitivetolossofMerlin-mediated,contact-dependentinhibitionofproliferationinvivoandthatthisisthecelloforiginofRCCinthismodelandperhapsinsomecasesofhumanRCC.MaterialsandMethodsSIMaterialsandMethodsprovidesfurtherdetails.AnimalsandAnimalProcedures.HomozygousNf2lox/loxmicewerekindlyprovidedbyM.Giovannini(51)andcrossedwithtransgenicmiceexpressingtheCrerecombinaseundertheVillinpromoter(Vil-Cre)kindlyprovidedbyS.Robine(31)ortheIFN-␣–inducibleMx1promoter(Mx1-Cre)[Tg(Mx1-Cre)1Cgn/J;JacksonLaboratory](52).TomonitorCre-mediatedexcision,micewerecrossedtoR26LSL-LacZ[B6;129-Gt(ROSA)26Sortm1Sho/J;JacksonLabora-tory]reportermice(53).Immunocompromised5-week-oldfemalenu/numicewereobtainedfromtheMassachusettsGeneralHospital(MGH)Cox7facility.Erlotinib(ChemieTek)wassolubilizedat10mg/mLina6%wt/volaqueoussolutionofCaptisol(CyDexPharmaceuticals).FourVil-Cre;Nf2lox/loxand4Nf2lox/loxcontrolmiceweretreatedbyi.p.injectionoferlotinibat100mg/kgbodyweightonceevery12hfor10days.TwoVil-Cre;Nf2lox/loxand2Nf2lox/loxcontrolmiceweretreatedonthesameschedulewithvehiclealone,withnodetectableeffect.Wechosetotreatmiceatanage(12–16weeks)whenallhaddevelopedasigniﬁcanttumorburdenbutnotumorshadacquiredinvasivecharacteristics.Atthisearlystage,tumorswerealsonotvascularized,andneitherapoptosisnornecrosiswasdetectable.AllanimalprocedureswereperformedaccordingtofederalandinstitutionalguidelinesandapprovedbytheMGHSubcommitteeonResearchAnimalCare.HistologyandImmunohistochemistry.Sectionswereincubatedovernightat4°Cwiththefollowingprimaryantibodies:BDBiosciences(␤-catenin,1:500,#610154),CellSignaling(anti-pAkt,1:50,#4060;Anti-pMAPK,1:200,#4370;andAnti-pSTAT3,1:50,#9145),Neomarkers(anti-Ezrin,1:200,#3C12;andanti-Vimentin,1:400,V9),andNovocastra(anti-Ki67,1:200).BrdU-labeledcellsweredetectedusingakit(Zymed)accordingtothemanufacturer’sinstructions.HRP-conjugatedsecondaryantibodies(usedforEzrin,Vimentin,andKi67)weredetectedusingtheDABperoxidasesubstratekit(VectorLaboratories).Biotin-ylatedsecondaryantibodies(for␤-catenin,pAkt,pMAPK,andpSTAT3)weredetectedusingtheABCimmunoperoxidasekit(VectorLaboratories).Immunofluorescence.Parafﬁnsectionswereincubatedovernightat4°Cwiththefollowingprimaryantibodies:CellSignaling(PH3,1:200,#9701;andP-Y100,1:1,000,#9411),Abcam(NHERF-1,1:200,#3452),andZymed(anti-ZO-1,1:60).PrimaryantibodiesweredetectedusingAlexaFluor488secondaryantibodies(Invitrogen),andslideswerecostainedwithDAPIandmounted(Vectashield;VectorLaboratories).Renalepithelialcellswerevisualizedbyautoﬂuorescenceat594nminparafﬁnsections.Cryosectionswereincubatedat37°C(30min)withbiotinylatedLotustetragonolobusagglutinin(1:80fromstocksolution;VectorLaboratories).Sectionsweresubsequentlyincubatedovernightat4°Cwithanti-␤-galactosidase(1:500,Cappel#55976).FITC–streptavidinandAlexaFluor594secondaryantibodieswereusedfordetec-tion,andslideswerecostainedwithDAPI.Imageswereacquiredasz-stacksonanOlympus1⫻81spinningdiskconfocalmicroscopewithaHamamatsuEMCCDdigitalcameraandprocessedusingSlidebookimagingsoftware(Olym-pus)andPhotoshopCS4(AdobeSystems).MorrisandMcClatcheyPNAS兩June16,2009兩vol.106兩no.24兩9771GENETICSImmunoblotting.Proteinsweredetectedusingthefollowingprimaryantibodies:CellSignaling(pEGFR,#2235;pSTAT-3,#9145;STAT-3,#4904;pAkt,#4060;Akt,#4685;pMAPK,#4370;MAPK,#4696;pErbB2,#2243;andTGF-␣,#3175,allat1:1,000),SantaCruzBiotechnology(NF2,#sc-331,1:2,000;ErbB2,#sc-284;andEGFR,#sc-03,bothat1:1,000;andHB-EGF,#sc-21593,1:200),BDBiosciences(E-cadherin,#610182;p120catenin,#610134;andCaveolin-1,#610407,allat1:2,000;␤-catenin,#610154,1:500;andpCaveolin,#611339,1:1,000),Sigma(actin,AC40,1:4,000;and␤-tubulin,#SAP-4G5,1:500),Abcam(Galectin-3,#A3A12,1:1,000),andNeomarkers(amphiregulin,AB-1,1:200).HRP-conjugatedsecondaryantimouseandantirabbitantibodieswerefromAmersham.PrimaryCultures.PrimaryculturesofrenalepithelialcellsweregeneratedbydissectionofPBS-ﬂushedkidneysusingmodiﬁedprotocols(54,55).Whereindi-cated,cellsweretreatedwith1␮MerlotiniborDMSOovernight.Mousewild-typeNf2cDNAwasclonedintoapuromycin-selectableretroviralpBabevectorfromapreviouslydescribedplasmid(22).Cellswereinfected,selected,andpassagedoncebeforeexperiments.Toevaluatecontact-inhibitionofcell-cycleprogression,conﬂuentcellsweretrypsinized,washedinPBS,ﬁxedovernightat⫺20°Cin70%ethanol,stainedfor30minwithpropidiumiodide(10␮g/mLinPBS),andanalyzedbyFACStoevaluateDNAcontent.Forxenograftexperiments,immunocompromisedmicewereinjecteds.c.with1⫻106prepassagecells(isolated,plated,andgrowntoconﬂuence)thathadbeentrypsinized,washedinPBSwith0.1%soytrypsininhibitor,andresuspendedinPBS.ACKNOWLEDGMENTS.WethankMarcoGiovanniniandSylvieRobineforNf2lox/loxandVillin-Cremice,respectively;OthonIliopoulos,JordanKreidberg,andMarcelloCurtoforadviceanddiscussion;RodBronson,SabinaSignoretti,andChin-LeeWuforpathologyconsultation;andAndrewGladdenandBrettMorrisforassistancewithFACSandimmunohistochemistry,respectively.ThisworkwassupportedbyNationalInstitutesofHealth(NIH)/NationalCancerInstituteGrantCA113733(toA.I.M.);NIH/NationalInstituteofGeneralMed-icalSciencesGrantT32GM07306(toZ.S.M.);andDepartmentofDefenseGrantW81XWH-05–1-0189(toA.I.M.).1.CohenHT,McGovernFJ(2005)Renal-cellcarcinoma.NEnglJMed353:2477–2490.2.ValladaresAyerbesM,etal.(2008)Originofrenalcellcarcinomas.ClinTranslOncol10:697–712.3.IliopoulosO(2006)Molecularbiologyofrenalcellcancerandtheidentiﬁcationoftherapeutictargets.JClinOncol24:5593–5600.4.MotzerRJ,BanderNH,NanusDM(1996)Renal-cellcarcinoma.NEnglJMed335:865–875.5.TakahashiM,KahnoskiR,GrossD,NicolD,TehBT(2002)Familialadultrenalneoplasia.JMedGenet39:1–5.6.KleymenovaE,etal.(2004)SusceptibilitytovascularneoplasmsbutnoincreasedsusceptibilitytorenalcarcinogenesisinVhlknockoutmice.Carcinogenesis25:309–315.7.GraveelC,etal.(2004)ActivatingMetmutationsproduceuniquetumorproﬁlesinmicewithselectiveduplicationofthemutantallele.ProcNatlAcadSciUSA101:17198–17203.8.PollardPJ,etal.(2007)Targetedinactivationoffh1causesproliferativerenalcystdevelopmentandactivationofthehypoxiapathway.CancerCell11:311–319.9.KobayashiT,etal.(2001)Agerm-lineTsc1mutationcausestumordevelopmentandembryoniclethalitythataresimilar,butnotidenticalto,thosecausedbyTsc2mutationinmice.ProcNatlAcadSciUSA98:8762–8767.10.KobayashiT,etal.(1999)Renalcarcinogenesis,hepatichemangiomatosis,andembry-oniclethalitycausedbyagerm-lineTsc2mutationinmice.CancerRes59:1206–1211.11.BabaM,etal.(2008)Kidney-targetedBirt-Hogg-Dubegeneinactivationinamousemodel:Erk1/2andAkt-mTORactivation,cellhyperproliferation,andpolycystickid-neys.JNatlCancerInst100:140–154.12.ChenJ,etal.(2008)DeﬁciencyofFLCNinmousekidneyledtodevelopmentofpolycystickidneysandrenalneoplasia.PLoSONE3:e3581.13.QianCN,etal.(2005)Cysticrenalneoplasiafollowingconditionalinactivationofapcinmouserenaltubularepithelium.JBiolChem280:3938–3945.14.SansomOJ,GrifﬁthsDF,ReedKR,WintonDJ,ClarkeAR(2005)Apcdeﬁciencypredis-posestorenalcarcinomainthemouse.Oncogene24:8205–8210.15.ForbesSA,etal.(2008)TheCatalogueofSomaticMutationsinCancer(COSMIC).CurrProtocHumGenetChapter10:Unit10.11.16.UhlmanDL,etal.(1995)Epidermalgrowthfactorreceptorandtransforminggrowthfactoralphaexpressioninpapillaryandnonpapillaryrenalcellcarcinoma:Correlationwithmetastaticbehaviorandprognosis.ClinCancerRes1:913–920.17.CurtoM,ColeBK,LallemandD,LiuCH,McClatcheyAI(2007)Contact-dependentinhibitionofEGFRsignalingbyNf2/Merlin.JCellBiol177:893–903.18.MochH,etal.(1997)Epidermalgrowthfactorreceptorexpressionisassociatedwithrapidtumorcellproliferationinrenalcellcarcinoma.HumPathol28:1255–1259.19.MerseburgerAS,etal.(2005)Membranousexpressionandprognosticimplicationsofepidermalgrowthfactorreceptorproteininhumanrenalcellcancer.AnticancerRes25:1901–1907.20.SmithK,etal.(2005)Silencingofepidermalgrowthfactorreceptorsuppresseshy-poxia-induciblefactor-2-drivenVHL-/-renalcancer.CancerRes65:5221–5230.21.ColeBK,CurtoM,ChanAW,McClatcheyAI(2008)Localizationtothecorticalcytoskel-etonisnecessaryforNf2/merlin-dependentepidermalgrowthfactorreceptorsilenc-ing.MolCellBiol28:1274–1284.22.LallemandD,CurtoM,SaotomeI,GiovanniniM,McClatcheyAI(2003)NF2deﬁciencypromotestumorigenesisandmetastasisbydestabilizingadherensjunctions.GenesDev17:1090–1100.23.AnanthS,etal.(1999)Transforminggrowthfactorbeta1isatargetforthevonHippel-Lindautumorsuppressorandacriticalgrowthfactorforclearcellrenalcarci-noma.CancerRes59:2210–2216.24.FranovicA,etal.(2007)Translationalup-regulationoftheEGFRbytumorhypoxiaprovidesanonmutationalexplanationforitsoverexpressioninhumancancer.ProcNatlAcadSciUSA104:13092–13097.25.dePaulsenN,etal.(2001)Roleoftransforminggrowthfactor-alphainvonHippel-Lindau(VHL)(-/-)clearcellrenalcarcinomacellproliferation:ApossiblemechanismcouplingVHLtumorsuppressorinactivationandtumorigenesis.ProcNatlAcadSciUSA98:1387–1392.26.GunaratnamL,etal.(2003)Hypoxiainduciblefactoractivatesthetransforminggrowthfactor-alpha/epidermalgrowthfactorreceptorgrowthstimulatorypathwayinVHL(-/-)renalcellcarcinomacells.JBiolChem278:44966–44974.27.PrewettM,etal.(1998)Mouse-humanchimericanti-epidermalgrowthfactorreceptorantibodyC225inhibitsthegrowthofhumanrenalcellcarcinomaxenograftsinnudemice.ClinCancerRes4:2957–2966.28.RowinskyEK,etal.(2004)Safety,pharmacokinetics,andactivityofABX-EGF,afullyhumananti-epidermalgrowthfactorreceptormonoclonalantibodyinpatientswithmetastaticrenalcellcancer.JClinOncol22:3003–3015.29.FoonKA,etal.(2004)PreclinicalandclinicalevaluationsofABX-EGF,afullyhumananti-epidermalgrowthfactorreceptorantibody.IntJRadiatOncolBiolPhys58:984–990.30.RavaudA,etal.(2008)Lapatinibversushormonetherapyinpatientswithadvancedrenalcellcarcinoma:ArandomizedphaseIIIclinicaltrial.JClinOncol26:2285–2291.31.elMarjouF,etal.(2004)Tissue-speciﬁcandinducibleCre-mediatedrecombinationinthegutepithelium.Genesis39:186–193.32.FaraggianaT,MalchiodiF,PradoA,ChurgJ(1982)Lectin-peroxidaseconjugatereactivityinnormalhumankidney.JHistochemCytochem30:451–458.33.YoungAN,etal.(2001)Expressionproﬁlingofrenalepithelialneoplasms:Amethodfortumorclassiﬁcationanddiscoveryofdiagnosticmolecularmarkers.AmJPathol158:1639–1651.34.SchneiderA,ZhangY,GuanY,DavisLS,BreyerMD(2003)Differential,induciblegenetargetinginrenalepithelia,vascularendothelium,andvisceraofMx1Cremice.AmJPhysiolRenalPhysiol284:F411–F417.35.SakakimaM,FujigakiY,YamamotoT,HishidaA(2008)AdistinctpopulationoftubularcellsinthedistalS3segmentcontributestoS3segmentregenerationinratsfollowingacuterenalfailureinducedbyuranylacetate.NephronExpNephrol109:e57–e70.36.KimK,LeeKM,HanDJ,YuE,ChoYM(2008)Adultstemcell-liketubularcellsresideinthecorticomedullaryjunctionofthekidney.IntJClinExpPathol1:232–241.37.MaeshimaA(2007)Label-retainingcellsinthekidney:Originofregeneratingcellsafterrenalischemia.ClinExpNephrol11:269–274.38.CaplanMJ,Seo-MayerP,ZhangL(2008)Epithelialjunctionsandpolarity:Complexesandkinases.CurrOpinNephrolHypertens17:506–512.39.CapaldoCT,MacaraIG(2007)DepletionofE-cadherindisruptsestablishmentbutnotmaintenanceofcelljunctionsinMadin-Darbycaninekidneyepithelialcells.MolBiolCell18:189–200.40.SuzukiA,OhnoS(2006)ThePAR-aPKCsystem:Lessonsinpolarity.JCellSci119(Pt6):979–987.41.SigismundS,etal.(2005)Clathrin-independentendocytosisofubiquitinatedcargos.ProcNatlAcadSciUSA102:2760–2765.42.KimYN,WiepzGJ,GuadarramaAG,BerticsPJ(2000)Epidermalgrowthfactor-stimulatedtyrosinephosphorylationofcaveolin-1.Enhancedcaveolin-1tyrosinephos-phorylationfollowingaberrantepidermalgrowthfactorreceptorstatus.JBiolChem275:7481–7491.43.SverdlovM,ShajahanAN,MinshallRD(2007)Tyrosinephosphorylation-dependenceofcaveolae-mediatedendocytosis.JCellMolMed11:1239–1250.44.WilsonSJ,etal.(2006)InhibitionofHER-2(neu/ErbB2)restoresnormalfunctionandstructuretopolycystickidneydisease(PKD)epithelia.BiochimBiophysActa1762:647–655.45.LatifZ,WattersAD,BartlettJM,UnderwoodMA,AitchisonM(2002)Geneampliﬁca-tionandoverexpressionofHER2inrenalcellcarcinoma.BJUInt89:5–9.46.MuthuswamySK,LiD,LelievreS,BissellMJ,BruggeJS(2001)ErbB2,butnotErbB1,reinitiatesproliferationandinducesluminalrepopulationinepithelialacini.NatCellBiol3:785–792.47.HagerM,etal.(2008)IncreasedactivatedAktexpressioninrenalcellcarcinomasandprognosis.JCellMolMed,inpress.48.MerseburgerAS,etal.(2008)ActivationofPI3Kisassociatedwithreducedsurvivalinrenalcellcarcinoma.UrolInt80:372–377.49.PantuckAJ,etal.(2007)PrognosticrelevanceofthemTORpathwayinrenalcellcarcinoma:Implicationsformolecularpatientselectionfortargetedtherapy.Cancer109:2257–2267.50.BrennerW,etal.(2002)LossoftumorsuppressorproteinPTENduringrenalcarcino-genesis.IntJCancer99:53–57.51.GiovanniniM,etal.(2000)ConditionalbiallelicNf2mutationinthemousepromotesmanifestationsofhumanneuroﬁbromatosistype2.GenesDev14:1617–1630.52.KuhnR,SchwenkF,AguetM,RajewskyK(1995)Induciblegenetargetinginmice.Science269:1427–1429.53.MaoX,FujiwaraY,OrkinSH(1999)ImprovedreporterstrainformonitoringCrerecombinase-mediatedDNAexcisionsinmice.ProcNatlAcadSciUSA96:5037–5042.54.TaubM(2005)Primarykidneyproximaltubulecells.MethodsMolBiol290:231–247.55.ChungSD,AlaviN,LivingstonD,HillerS,TaubM(1982)Characterizationofprimaryrabbitkidneyculturesthatexpressproximaltubulefunctionsinahormonallydeﬁnedmedium.JCellBiol95:118–126.56.RobineS,JaisserF,LouvardD(1997)Epithelialcellgrowthanddifferentiation.IV.Controlledspatiotemporalexpressionoftransgenes:Newtoolstostudynormalandpathologicalstates.AmJPhysiol273(4Pt1):G759–762.57.MaeshimaA,YamashitaS,NojimaY(2003)Identiﬁcationofrenalprogenitor-liketubularcellsthatparticipateintheregenerationprocessesofthekidney.JAmSocNephrol14:3138–3146.9772兩www.pnas.org兾cgi兾doi兾10.1073兾pnas.0902031106MorrisandMcClatchey